June 2014

CURRICULUM VITAE

James D. Neaton

Name: James Dennis Neaton

Title: Professor of Biostatistics, Adjunct Professor of Medicine, Distinguished International Professor

Address: Coordinating Centers for Biometric Research
Division of Biostatistics
School of Public Health
University of Minnesota
2221 University Avenue SE, Suite 200
Minneapolis MN 55414

Birth Date: September 20, 1947

Place of Birth: Galveston, Texas

Citizenship: U.S.A.

Education:

		Major Field	Degree
Lamar University	1965-1968	Mathematics	None
University of Minnesota School of Public Health Biometry Division	1968-1969	Biometry	B.A.
University of Minnesota	1969-1970	Biometry	M.S.
University of Minnesota	1984	Biometry	Ph.D.

Honors: B.A. Awarded with Honors
Pi Mu Epsilon
Delta Omega Honorary Public Health Society
Leonard M. Schuman Excellence in Teaching Award (2001)
Fellow, American Statistical Association (1994)
Fellow, Society for Clinical Trials (2009)
Academic Health Center Academy for Excellence in Health Research (2009)
University of Minnesota Global Engagement Award (2010)
Lillehei Heart Institute (2013)

Membership in Professional Societies:

Society for Clinical Trials, President 2006-2007
Biometric Society, ENAR
American Statistical Association
American Heart Association Council on Epidemiology
International Society and Federation of Cardiology, Scientific Section on Epidemiology and Prevention
International AIDS Society

Professional Experience:

Professor, Biostatistics Division, School of Public Health, University of Minnesota, 1995 - present

Adjunct Professor of Medicine, Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, 2006-present.

Associate Professor, Biostatistics Division, School of Public Health, University of Minnesota, 1990 - 1995

Assistant Professor, Biostatistics Division, School of Public Health, University of Minnesota, 1985 - 1990

Research Fellow, Biometry Division, School of Public Health, University Minnesota, 1973 - 1985

USPHS Officer Assigned to Biometrics Research Branch, National Heart and Lung Institute, NIH, 1970-1972.

Grant and Contract Support:

Principal Investigator, NIH (NIAID, NHLBI, NIAMS, NIMH, NINDS) International Network for Strategic Initiatives in Global HIV Trials (INSIGHT), 2006 - Present.

Principal Investigator, subcontract to SAIC (NCI prime) Observational studies of pandemic H1N1 influenza, 2009 - Present.

Principal Investigator, subcontract to SAIC (NCI prime) Clinical trial of IVIG for influenza, 2013 - Present.

Principal Investigator, NIH (NHLBI, NCATS) Summer Institute for Training in Biostatistics (SIBS), 2013 – Present.

Co-Director, NIH Roadmap Multidisciplinary Clinical Research Career Development Program (K12), 2005-2011.

Principal Investigator, Coordinating Center for the SILCAAT Study sponsored by Chiron and the National Institutes of Health, 2003 - 2009.

Principal Investigator, NIAID Statistical Center and Data Management Center for Community Programs for Clinical Research on AIDS, 1990 - 2006.

Principal Investigator, NIAID International Trial of IL-2 (ESPRIT), 1999- 2006.

Principal Investigator, NHLBI Extended Mortality and Follow-up and Analyses of Men in the MRFIT, 2001 –2006.

Principal Investigator, Coordinating Center, Pharmacia/Searle CONVINCE Study, 1996 - 2004.

Director, Biostatistics Core, NCI Great Lakes Center for AIDS Research, 1998- 2003.

Principal or Co-Principal Investigator, NHLBI Multiple Risk Factor Intervention Trial (MRFIT) Coordinating Center, 1973 - 1999.

Principal Investigator, NHLBI Mortality Surveillance of MRFIT Screenees, 1989-1999.

Co-Principal Investigator and Director of the Coordinating Center for NHLBI Treatment of Mild Hypertension Study (TOMHS), 1985 - 1996.

Co-Investigator of primary grant and Principal Investigator of Statistical Center for a Prospective Study of Blood Pressure and ESRD, 1991 - 1996.

Co-Principal Investigator and Director of Data Coordinating Center for NHLBI Study of Potassium and Sodium to Control Blood Pressure in Hypertensives, 1983 - 1988.

Co-Investigator, NEI Diabetic Retinopathy Vitrectomy Study: 1975-1980

Co-Investigator, NHLBI Granulocyte Transfusion Study, 1977-1979

Editorial and Advisory Committees:

President, Society for Clinical Trials, 2006-2007

Editor in Chief, *Controlled Clinical Trials,* 1999-2003.

Advisory Board, *Clinical Trials,* 2004-2013.

Chair, Society for Clinical Trials Publication Committee, 2012 – present.

Chair, MRFIT Editorial Committee, 1997- 2006.

NHLBI ALLHAT External Advisory Committee, 2011-present.

NIDDK, Diabetes Prevention Trial Outcomes Data and Safety Monitoring Board, 2011-present.

NIDDK, Vitamin D and Type 2 Diabetes Data and Safety Monitoring Board, 2013- present.

U.S. Public Health Service - Infectious Disease Society Joint Task Force on Prevention of Opportunistic Infection in Patients with HIV-Infection, 1994 – 2010.

U.S. Public Health Service - Panel on Clinical Practices for the Treatment of HIV Infection, 1999 - 2011.

External Advisory Committee, Institute for Clinical and Translational Research, University of Wisconsin, 2008-2012.

Consultant, Minimal Standards in the Prevention and Handling of Missing Data in Observational and Experimental Patient Centered Outcomes Research, Johns Hopkins University, PCORI contract, 2012.

External Reviewer of NHLBI Joint National Committee Report on Blood Pressure, 2012.

Cardiovascular and Renal Drugs Advisory Committee, 2007- 2011.

National Academy of Sciences, Committee on National Statistics Oversight Committee for Workshop on Handling Missing Data in Clinical Trials, 2009-2010.

FDA, Clinical Trials Transformation Initiative, Project Team for Effective and Efficient Monitoring, 2009-2010.

NIH Director's Clinical Research Roadmap Meeting, 2003.

NIH Director's Meeting for Investigators on Open Access, 2004.

NHLBI Strategic Planning Group, 2006.

NIDDK, Extramural Advisory Committee, Special Statutory Funding Program for Type 1 Diabetes Research, 2008 and 2013

NHLBI Working Group on Clinical Use of Ventricular Assist Devices, 2008.

TrialNet External Advisory Committee, NIDDK, NIH, 2006-2011.

Consultant, South Africa PHIDISA Project, NIH, 2003 - Present.

Data Monitoring Committee, Centers for Disease Control Clinical Trials on the Treatment of Tuberculosis, 1996 - Present.

Data and Safety Monitoring Board, Bill and Melinda Gates Foundation Study of Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition within HIV-1 Discordant Couples, 2008-2013.

Data and Safety Monitoring Board, NIAID (HPTN 039) Acyclovir for the Reduction of HIV Acquisition, 2002 - 2008.

Data and Safety Monitoring Committee, Harvard Clinical Research Institute Dual Antiplatelet Therapy (DAPT) Trial, 2009 - 2014.

Data and Safety Monitoring Committee, NCI, NIH Polyp Prevention Study, 2005 - 2013.

Data and Safety Monitoring Committee, Pfizer Phase 3 Program of PCSK9 Inhibition and Reduction in Risk of Vascular Events, 2013 - present.

Data and Safety Monitoring Board, NIDDK, NIH D2d Study of Diabetes Prevention, 2013 - present.

Data and Safety Monitoring Board, Trevena Phase 2 Study of TRV027 for Acute Decompenstated Heart Failure, 2013 - present.

Data and Safety Monitoring Board, NIDDK Wisconsin Cystic Fibrosis Neonatal Screening Project, 2003 - 2011.

Data and Safety Monitoring Board, NHLBI Systolic Blood Pressure Intervention Trial (SPRINT), 2010 - Present.

Steering Committee, Yale University Open Data Access Project (YODA), 2011 - present.

External Data Monitoring Committee, Merck, V212, Inactivated Varicella Zoster Virus Vaccine, Studies, 2010- present.

Data and Safety Monitoring Board, Bristol-Myers Squibb I-Preserve Heart Failure Trial, 2003-2007.

Data Monitoring Committee, Astellas Phase 2 Study of ASKP1240 for Kidney Transplant Recipients, 2013- present.

Data and Safety Monitoring Board, Amgen, Etanercept in Pediatric Patients with Plaque Psoriasis, 2004-2012.

Data and Safety Monitoring Board, St. Jude Medical, Left Atrial Pressure Monitoring to Optimize Heart Failure (LAPTOP), 2010-2014.

Data and Safety Monitoring Board, Takeda, Cardiovascular outcomes in patients with type 2 diabetes, 2011-present.

Data and Safety Monitoring Committee, Astra-Zeneca, Inhaled corticosteroids and serious asthma-related events, 2011-present.

Executive Committee, Phentermine/Topirmate Outcomes Trial, Vivus, 2011 - present.

External Reviewer, Institute of Medicine Report, Methodological Challenges in Biomedical HIV Prevention Trials, 2008.

Data and Safety Monitoring Committee, Bristol Myers Squibb, Clinical trial of IL-6 blocker for Crohn's Disease, 2012-2014.

Data and Safety Monitoring Board, Biocontrol, INNOVATE Heart Failure Trial, 2009-present.

Framingham Heart Study, Observational Study Monitoring Board, NIH, NHLBI, 2001 - present.

Steering Committee, Merck Research Laboratories Losartan HEAAL Study, 2001 - 2010.

Member, DSMB, Medtronic REDUCE HF Trial, 2007 - 2009.

Chair, DSMB, Merck Phase IV Clinical Trial to Evaluate the Safety and Tolerability of ZOSTAVAX, 2007-2009

Advisory Committee, Inventory and Evaluation of Clinical Research Networks (IECRN), NIH Roadmap Project, Westat, 2005-2006.

Member, DSMB, Medtronic COMPASS Heart Failure Trial, 2004-2005.

Chair, Data and Safety Monitoring Board, Merck Research Laboratories APPROVe Trial, 2001-2004.

Chair, Data and Safety Monitoring Board, Merck Research Laboratories VIOXX Prostate Cancer Trial and Combined Analysis of CV Events, 2003 - 2004.

Data and Safety Monitoring Board, Acorn Medical Device Trial, 2002 - 2004.

Data Monitoring Committee, Veterans Administration Trial on Varicella Vaccine for the Prevention of Herpes Zoster and its Complications, 1999 - 2004.

Steering Committee, Searle/Pharmacia EPHESUS Study, 1999 - 2003.

NIH Gene Transfer Clinical Trials Design Working Group, 2004 - 2005.

Data Monitoring Committee, Abbott Laboratories Trial of Depakote in the Elderly, 1999 - 2002.

Data and Safety Monitoring Board, St. Jude Medical Trial on SJM Regent/Epic Heart Valve, 2000 - 2006.

Data and Safety Monitoring Board, St. Jude Prospective Study of Trifecta Valve, 2007 - 2011.

Steering Committee, Merck Research Laboratories Losartan ELITE II Study, 1997 - 2000.

Data Monitoring Committee, Regeneron Pharmaceuticals Trial of r-methHuBDNF for ALS, 1998 - 2001.

Data and Safety Monitoring Committee, Merck Research Laboratories Vioxx Gastrointestinal Outcomes Research Study (VIGOR), 1999 - 2000.

HIVNET Prevention Research Review Group, NIAID, 1995 - 1998.

Data Monitoring and Safety Committee, NICHD Maternal-Fetal Medicine Units Network, 1991 - 1996.

Data and Safety Monitoring Board, NHLBI Dietary Approaches to Stop Hypertension (DASH) trial, 1994 - 1996.

Data and Safety Monitoring Committee, Merck Research Laboratories Losartan ELITE Study, 1994 - 1996.

Data and Safety Monitoring Committee, Glaucoma Research Foundation Trial of Intraocular pressure reduction in normal-tension glaucoma, 1996-1998.

Data and Safety Monitoring Committee, Glaxo 3TC Clinical Endpoint Protocol NUCB3007, 1995 - 1996.

Data Monitoring Board, NHLBI Prevention and Treatment of Hypertension Study, 1988 - 1994

Data and Safety Monitoring Committee, VA-NHLBI Trial of Reduction of Alcohol Intake in Lowering Blood Pressure, 1989 - 1995

Data Monitoring Committee, NHLBI Sodium and Hypertension in Blacks, 1992 - 1995.

Data Monitoring Committee, NHLBI Women's Healthy Lifestyle Project, 1992 - 1995.

Data Monitoring Committee, NIDDK African American Study of Kidney Disease and Hypertension, 1992 - 1994

NIH Ad Hoc Data and Safety Monitoring Review Committee on Human Growth Hormone in Turner Syndrome, 1992 - 1993

Data Monitoring Committee, Children and Adolescent Blood Pressure Program, 1986-1990.

Special Review Committee, NCI National Bladder Cancer Project, Collaborative Group A, 1976 - 1982.

Policy Advisory Committee, NICHD Sudden Infant Death Syndrome Study, 1977 - 1984.

Participant, Keystone Dialogue (initiated by Vice-President Gore) on Establishment of Studies to Optimize Medical Management of HIV Infection, 1996.

NIH gp160 Trial Design Team, NIAID, 1992.

Member, Joint National Committee V on Detection, Evaluation and Treatment of High Blood Pressure (Subcommittee No. 1 on Definition, Prevalence, Evaluation, Screening and Goals of Therapy), 1992.

Consultant, Minnesota Department of Health, Impact of Vaccination on Haemophilus Disease Incidence, 1986 - 1992.

Consultant, Minnesota Department of Health, Smoking Cessation Protocol for Primary Care Physician Offices, 1987 - 1990.

Seminar Committee and Faculty Member, International Teaching Seminar on Cardiovascular Disease Epidemiology and Prevention, 1987 - 1994.

Scientific Program Committee, American Heart Association, 1984 - 1987.

Scientific Program Committee, 2nd Joint Meeting of the Society for Clinical Trials and the International Society for Clinical Biostatistics, 1997.

Scientific Program Committee, XIth, XIIth, XIIIth, XIVth, XVth and XIXth International Conferences on AIDS, 1996, 1998, 2000, 2002, 2004, 2012 and 2013.

Plus ad hoc committee assignments with NIH and consultations with the Food and Drug Administration and the pharmaceutical industry.

Publications, including Peer-Reviewed Papers, Letters, Commentaries, and Book Chapters:

1. Urokinase Pulmonary Embolism Trial Group. The Urokinase Pulmonary Embolism Trial: a national cooperative study. Circulation 47:1-108, 1973.

2. Urokinase-Streptokinase Pulmonary Embolism Trial Group. Urokinase-Streptokinase Pulmonary Embolism Trial JAMA 229:1606-1613, 1974.

3. Multiple Risk Factor Intervention Trial Group. Design Considerations in the NHLI Multiple Risk Factor Intervention Trial (MRFIT). J. Chronic Diseases, 30:261-275, 1977.

4. Multiple Risk Factor Intervention Trial Group. The MRFIT Behavior Pattern Study. I. Study Design, Procedures, and Reproducibility of Behavior Pattern Judgements. J. Chronic Diseases, 32:293-305, 1978.

5. Kuller L, Neaton JD, Caggiula A, Falvo-Gerard L. Primary Prevention of Heart Attacks: The Multiple Risk Factor Intervention Trial. Am J Epidemiol, 112:185-1999, 1980.

6. Neaton JD, Broste S, Cohen L, Fishman E, Kjelsberg M. The Multiple Risk Factor Intervention Trial (MRFIT) VII. A Comparison of Risk Factor Changes Between the Two Study Groups. Prev Med 10:519-543, 1981.

7. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: Risk Factor Changes and Mortality Results. JAMA, 248:1465-1477, 1982.

8. Kuller L, Hulley SB, Laporte R, Neaton JD, Dai W. Environmental determinants, liver function and high density lipoprotein cholesterol levels. Am J Epidemiol, 117:406-418, 1983.

9. Wentworth D, Neaton JD, Rasmussen W. An Evaluation of the Social Security Administration MBR File and the National Death Index in the Ascertainment of Vital Status. Am. J. Public Health, 73:1270-1274, 1983.

10. Neaton JD, Kuller L, Wentworth D., Borhani N. Total and Cardiovascular Mortality in Relation to Cigarette Smoking, Serum Cholesterol Concentration and Diastolic Blood Pressure Among Black and White Men Followed 5 Years. American Heart Journal, 108:759-770, 1984.

11. Multiple Risk Factor Intervention Trial Research Group. Exercise Electrocardiogram and Coronary Heart Disease Mortality in the Multiple Risk Factor Intervention Trial. Amer. J. Cardiology, 5:16-23, 1985.

12. Multiple Risk Factor Intervention Trial Research Group. Relationship Among Baseline Resting Electrocardiographic Abnormalities, Antihypertensive Treatment, and Mortality in the Multiple Risk Factor Intervention Trial. Amer. J. Cardiology, 5:1-15, 1985.

13. Grimm RH, Cohen JD, Smith W, Falvo-Gerard L, Neaton JD. Hypertension Management in the Multiple Risk Factor Intervention Trial (MRFIT): Six Year Intervention Results for Special Intervention and Usual Care Men. Archives of Internal Medicine, Vol. 145, July, 1985.

14. Grimm RH, Neaton JD, McDonald M, et al. Beneficial Effects from Systematic Dosage Reduction of the Diuretic Chlorthalidone: A Randomized Study Within a Clinical Trial. American Heart Journal, 109:858-864, 1985.

15. Grimm RH, Elmer PH, Neaton, JD, Segal MS, Prineas RJ. Role of Potassium Supplementation and Sodium Reduction in Controlling Blood Pressure in Hypertensive Men: Design and Methods of the Mt. Sinai Hypertension Trial. Edited by Paul K Whelton and Andrew Whelton, Marcel Dekker, Inc, New York, 1985.

16. Tillotson J, Neaton JD. Forms designed for implementation or evaluation of the MRFIT intervention process. In Materials and Methods for a cardiovascular disease risk factor reduction program. Edited by Jeanne Tillotson and SB Hulley. NIH Publication No. 85-1267, DHEW, March, 1985.

17. Grimm RH, Neaton JD, Ludwig B. The Prognostic Importance of Total White Blood Cell Count for All Cause, Cardiovascular and Cancer Mortality. JAMA, 254:1932-1937, 1985.

18. Cutler JA, Neaton JD, Hulley SB, Stamler J. Coronary Heart Disease and All Cause Mortality in the Multiple Risk Factor Intervention Trial: Overall and Subgroup Findings. Preventive Medicine, 14:293-311, 1985.

19. Shekelle RB, Hulley SB, Neaton JD, Billings J, Borhani N, et al. The MRFIT Behavior Pattern Study. II. Type A Behavior and Incidence of Coronary Heart Disease. Amer. J. Epid., 122:559-570, 1985.

20. Kuller LH, Hulley SB, Cohen JD, Neaton JD. Unexpected Effects of Treating Hypertension in Men with ECG Abnormalities: A Review of the Evidence. Circulation, 73:114-123, 1986.

21. Stamler J, Wentworth D, Neaton JD. Prevalence and prognostic significance of hypercholesterolemia in men with hypertension. Am. J. Med., 80:33-39, 1986.

22. Watkins LO, Neaton JD, Kuller, LH. Racial Differences in High-Density Lipoprotein Cholesterol and Coronary Heart Disease Incidence in the Usual Care Group of the Multiple Risk Factor Intervention Trial. Am. J. Cardio., 57:538-545, 1986.

23. Rautaharju PM, Prineas RJ, Furburg CD, Neaton JD, Crow RS, Stamler J. The prognostic value of exercise ECG in men at high risk of future coronary heart disease: Multiple Risk Factor Intervention Trial (MRFIT) Experience. J. Amer. College Cardio., 8:668-686, 1986.

24. Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial (MRFIT): Coronary Death, Non-Fatal Myocardial Infarction, and Other Clinical Outcomes. Amer. J. Cardio., 58:1-13, 1986.

25. Multiple Risk Factor Intervention Trial Research Group. Relationship Between Baseline Risk Coronary Heart Disease and Total Mortality in the Multiple Risk Factor Intervention Trial (MRFIT). Prev. Med., 15:254-273, 1986.

26. Kannel WB, Neaton JD, Wentworth D, Thomas HE, Stamler J, Hulley SB, Kjelsberg MO. Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Amer. Heart J., Vol. 112, No. 4, 825-836, 1986.

27. Stamler J, Wentworth D, Neaton J. Is relationship Between Serum Cholesterol and Risk of Premature Death From Coronary Heart Disease Continuous and Graded? JAMA, Vol. 256, No. 20, 2823-2828, 1986.

28. Shekelle RB, Hulley SB, Neaton JD, et al. Type A behavior and risk of coronary heart disease in the Multiple Risk Factor Intervention Trial. In Biological and Psychological Factors in

Cardiovascular Disease. Edited by T.H. Schmidt, T.M. Dembroski and G. Blumenchen, Springer-Verlag, Berlin 1986.

29. DuChene AG, Hultgren DH, Neaton JD, Grambsch PV, et al. Forms Control and Error Detection Procedures Used at the Coordinating Center of the Multiple Risk Factor Intervention Trial. Controlled Clinical Trials (Suppl.), Vol. 7, No. 3, 345-455, 1986.

30. Neaton JD, Kannel WB, Wentworth D et al. Smoking plus hyper-cholesterolemia and coronary risk. Letter to the Editor. Amer. Heart J., 1527-1528, 1987.

31. Grimm RH, Tillinghast L, Daniels K, Neaton JD, Mascioli S, Crow R, Pritzker M, Prineas R. Unrecognized myocardial infarction: Experience in the Multiple Risk Factor Intervention Trial (MRFIT). Circulation, Vol. 75 (Suppl. II), II-6 - II-8, 1987.

32. MacMahon SW, Cutler JA, Neaton JD, et al. Relationship of blood pressure to coronary and stroke morbidity and mortality in clinical and epidemiological studies. J. Hypertension, 4 (Suppl. 6), S14-S17, 1987.

33. Stamler J, Prineas RJ, Neaton JD, Grimm RH, et al. Background and design of the new U.S. trial on diet and drug treatment of "mild" hypertension (TOMHS). Am J. Cardiology, 59:512-602, 1987.

34. Grimm RH, Neaton JD, Prineas RJ. Primary prevention trials and the rationale for treating mild hypertension. Clinical Therapeutics, Vol. 9, Suppl. D, 20-30, 1987.

35. Cohen JD, Neaton JD, Prineas RJ, Daniels KA. Diuretics, serum potassium and ventricular arrhythmias in the Multiple Risk Factor Intervention Trial. Am. J. Cardiology, 60:548-554, 1987.

36. Rautaharju PM, Neaton JD. Electrocardiographic abnormalities and coronary heart disease mortality among hypertensive men in the Multiple Risk Factor Intervention Trial. Clinical and Investigative Med, 10:606-615, 1987.

37. Abdalla ISH, Prineas RJ, Neaton JD, et al. Relation between ventricular premature complexes and sudden cardiac death in apparently healthy men. Am. J. Cardiology, 60:1036-1042, 1987.

38. Rutan GH, Kuller LH, Neaton JD, et al. Mortality associated with diastolic and isolated systolic hypertension among men screened for the Multiple Risk Factor Intervention Trial. Circulation 77:504-514, 1988.

39. Neaton JD, Grimm RH, Cutler JA. Recruitment of participants for the Multiple Risk Factor Intervention Trial (MRFIT). Cont Clinical Trials 8:41S-53S, 1988.

40. Osterholm MT, Rambeck JH, White KE, Jacobs JL, Pierson LM, Neaton JD, Hedberg CW et al. Lack of efficacy of Haemophilus b polysaccharide vaccine in Minnesota. JAMA 260:1423-1428, 1988.

41. Shekelle RB, Hulley SB, Neaton JD, Borhani NO et al. Type A behavior (Letters to the Editor) Amer. Heart J 115:1348-1350, 1988.

42. Gordon DJ, Probstfield JL, Garrison, RJ, Neaton JD, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 79:8-15, 1989.

43. MacMahon S, Collins G, Rautaharju P, Cutler JW, Neaton, JD, Prineas R, Crow R, Stamler J. Electrocardiograph left ventricular hypertrophy and the effects of antihypertensive drug therapy in

hypertensive participants in the Multiple Risk Factor Intervention Trial. Am. J. Cardiology 63:202-210, 1989.

44. Grimm RH, Kofran PM, Neaton JD et al. Effect of potassium supplementation combined with dietary sodium reduction on blood pressure in men taking antihypertensive medication. J. Hypertension 6 (Suppl. 4), S591-S593, 1989.

45. Stamler J, Neaton JD, Wentworth, DN. Blood pressure (systolic and diastolic) and risk of fatal coronary heart disease. Hypertension, 13 (Suppl. I), 2-12, 1989.

46. Iso H, Jacobs DR, Wentworth D, Neaton JD, Cohen J. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial. N Engl J Med 320:904-910, 1989.

47. Grimm RH, Neaton JD, Elmer PJ, Svendsen KH, et al. The influence of potassium on blood pressure in hypertensive men on a low sodium diet: Results of a double-blind randomized trial. N Engl J Med 322:571-574, 1990.

48. Neaton JD, DuChene AG, Svendsen, KH, Wentworth D. An examination of the efficiency of some quality assurance methods commonly employed in clinical trials. Statistics in Medicine, 9:115-124, 1990.

49. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R et al. Blood pressure, stroke and coronary heart disease, Part I: Effects of prolonged differences in blood pressure - evidence from nine prospective observational studies corrected for the regression dilution bias. Lancet, 335:765-774, 1990.

50. Multiple Risk Factor Intervention Trial Research Group. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial. Findings related to a priori hypothesis of the trial. JAMA 263:1795-1801, 1990.

51. Hung J, Huang T, Wu D, Yen M, Tsai S, Dahl H, Neaton JD, Dahl JC. The impact of dietary sodium, potassium and calcium on blood pressure. J. Formosan Med. Assoc 89:17-22, 1990.

52. Multiple Risk Factor Intervention Trial Research Group. Mortality after 10.5 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation, 82:1616-1628, 1990.

53. Mascioli S, Grimm RH, Neaton JD, Stamler J, et al. The Treatment of Mild Hypertension Study (TOMHS): Characteristics of participants at baseline. Amer. J. Cardiol, 66:32C-35C, 1990.

54. Hanson LK, Grimm RH, Neaton JD. The relationship of white blood cell count to other cardiovascular risk factors. Int J Epid, 19:881-888, 1990.

55. Mascioli S, Grimm RH, Launer C, Svendsen K, Flack J, Gonzalez N, Elmer P, Neaton JD. Sodium chloride raises blood pressure in normotensives: The Study of Sodium and Blood Pressure. Hypertension, 17:I21-I26, 1991.

56. Treatment of Mild Hypertension Research Group. The Treatment of Mild Hypertension Study (TOMHS): A randomized, placebo controlled trial of a nutritional-hygienic regimen along with various drug monotherapies. Arch Int. Med., 151:1413-1423, 1991.

57. Neaton JD, Bartsch G, Broste S, Cohen J, Simon N. A case of data alteration in the Multiple Risk Factor Intervention Trial. Cont Clin Trials, 12:731-740, 1991.

58. Ruth KE, Neaton JD. Evaluation of two biological markers of tobacco exposure. Prev Med 20:574-589, 1991.

59. Kuller L, Ockene J, Meilahn E, Wentworth D, Svendsen K, Neaton J. Cigarette smoking and mortality. Prev Med 20:638-654, 1991.

60. Shaten BJ, Kuller L, Neaton JD. Association between baseline risk factors, cigarette smoking and CHD mortality after 10.5 years. Prev Med 20:655-669, 1991.

61. Stamler J, Neaton JD, Wentworth D, Shih J et al. Lifestyles and life-style related risk factors: their combined impact in producing epidemic cardiovascular disease and the potential for prevention (in "Multiple Risk Factors for Cardiovascular Disease," edited by A.M. Gotto, C. Lenfant, R. Paoletti and M. Some), Norwell; Kluwer, 19-25, 1992.

62. Phillips AN, Neaton JD, Cook DG, Grimm RH, Shaper AG. The white blood cell count and risk of lung cancer. Cancer 69:681-684, 1992.

63. Davey-Smith G, Neaton JD, Ben-Shlomo Y, Shipley M, Wentworth D. Serum Cholesterol Concentration and Primary Brain Tumors: A Prospective Study. Amer J Epid, 135:259-265, 1992.

64. Neaton JD, Wentworth D. Influence of serum cholesterol, blood pressure, and cigarette smoking on death from coronary heart disease in 316,099 white men age 35-57 years: Overall findings and differences by age. Arch Int Med 152:56-64, 1992.

65. Neaton JD, Blackburn H, et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Int Med 152:1490-1500, 1992.

66. Pearce KA, Grimm RH, Rao S, Svendsen K, Liebson PR, Neaton JD. Population-derived comparisons of ambulatory and office blood pressures; implications for the determination of usual blood pressure and the concept of white coat hypertension. Arch Int Med 152:750-756, 1992.

67. Phillips AN, Neaton JD, Cook DG, Grimm RH, Shaper AG. Leukocyte count and risk of major coronary heart disease events. Amer. J. Epid., 136:59-70, 1992.

68. Davey Smith G, Phillips AN, Neaton JD. Smoking as "independent" risk factor for suicide: Illustration of an artifact from observational epidemiology? Lancet, 340:709-712, 1992.

69. Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, McMillan G, Neaton J et al. Report of the conference on low blood cholesterol: Mortality associations. Circulation, 86:1046-1060, 1992.

70. Stamler J, Stamler R, Neaton JD. National high blood pressure education program 20 years of achievement. Chapter 6: Blood pressure and cardiovascular risks: U.S. population data. NHLBI, 1992.

71. Neaton JD, Bartsch GE. Impact of measurement error and temporal variability on the estimation of event probabilities for risk factor intervention trials. Stat Med, 11: 1719-1729, 1992.

72. Walker WG, Neaton JD, Cutler JA, Neuwirth R, Cohen JD. Changes in serum creatinine in hypertensive participants in the Multiple Risk Factor Intervention Trial (MRFIT): Evidence that lowering blood pressure protects renal function in mild to moderate hypertensives. JAMA 268:3085-3091, 1992.

73. Eichner JE, Kuller LH, Orchard TJ, Grandits GA, McCallum LM, Ferrell RE, Neaton JD. The relationship of apolipoprotein E phenotype to myocardial infarction and CHD mortality. Amer. J. Cardiology, 71:160-165, 1993.

74. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12 year cardiovascular mortality for men screened for the Multiple Risk Factor Intervention Trial. Diabetes Care, 16:434-444, 1993.

75. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks; U.S. Population Data. Archives Int. Med.,153:598-615, 1993.

76. Stamler J, Dyer AR, Shekelle RB, Neaton JD, Stamler R. Relationship of baseline major risk factors to coronary and all cause mortality, and to longevity: Findings from long-term follow-up of Chicago cohorts. Cardiology, 82(2-3):191-222, 1993.

77. Flack JM, Neaton JD, Daniels B, Esunge P. Ethnicity and renal disease. Lessons from MRFIT and TOMHS. Amer. J. Kidney Diseases, 21 (Suppl):31-40, 1993.

78. Neaton JD, Grimm RH, Prineas RJ, Grandits G, et al for the Treatment of Mild Hypertension Study Research Group. Treatment of Mild Hypertension Study (TOMHS): Final Results JAMA 270:713-724, 1993.

79. Stamler R, Stamler J, Brown WV, Gotto AM, Greenland P, Grundy S, Hegsted M, Leupker RV, Neaton JD, Steinberg D, Stone NJ, Van Horn L, Wissler RW. Serum Cholesterol: Doing the right thing. Circulation, 88:1954-1960, 1993.

80. Stamler R, Stamler J, Brown WV, Gotto AM, Greenland P, Grundy S, Hegsted M, Leupker RV, Neaton JD, Steinberg D, Stone NJ, Van Horn L, Wissler RW. Reply to Letters to the Editor on Editorial, "Serum Cholesterol: Doing the right thing". Circulation, 90:2573-2577, 1993.

81. Shaten BJ, Davey-Smith G, Kuller LH, Neaton JD. Risk factors for the development of Type 2 diabetes amoung men enrolled in the usual care group of Multiple Risk Factor Intervention Trial (MRFIT). Diabetes Care, 16:1331-1339, 1993.

82. Neaton JD, Wentworth DN, Kuller L. Risk factors for death from different types of strokes. Annals of Epid., 3: 493-499, 1993.

83. Jacobson M, Besch CL, Child C, Hafner R, Matts JP, Muth K, Wentworth DN, Neaton JD, Deyton L. Prophylaxis with pyrimethamine for toxoplasmic encephalitis in patients with advanced HIV disease: Results of a randomized trial. J. Infectious Diseases, 169:384-394, 1994.

84. Lund EM, James KM, Neaton JD. Clinical trial design: veterinary perspectives. Journal of Veterinary Internal Medicine, 8:317-322, 1994.

85. Coughlin SS, Neaton JD, Sengupta A, Kuller LH. Predictors of mortality from idiopathic dilated cardiomyopathy in 356,222 men screened for the Multiple Risk Facter Invervention Trial. Amer. J. Epid, 139:166-172, 1994.

86. Abrams D, Goldman A, Launer C, Korvick J, Neaton JD, et al. A comparative trial of didanosine and zolcitabine in patients with human immunodeficiency virus infection who are intolerant or have failed zidovudine therapy N Engl J Med, 330:657-662, 1994.

87. Stamler J, Neaton JD. Benefits of lower cholesterol Scientific American, Science and Medicine, 1:28-37, 1994.

88. Zhou SH, Rautaharju PM, Prineas RJ, Neaton JD, et al. Improved ECG models for estimation of LVH progression and regression incidence by redefinition of the criteria for a significant change in LVH status. J. Electrocard, 26:108-113, 1994.

89. Neaton JD, Wentworth DN, Rhame F, Hogan C, Deyton L. Considerations in choice of a clinical endpoint for AIDS clinical trials. Stat Med, 13:2107-2125, 1994.

90. Egger M, Neaton JD, Phillips AN, Davey-Smith G. Zidovudine and the risk of death: meta-analysis of randomized placebo controlled trials. Letter to the Editor. Lancet 343:1355, 1994.

91. Phillips AN, Sabin CA, Davey-Smith G, Egger M, Neaton JD. The European-Australian Collaborative Group Study 017 (letter to the Editor). AIDS 8:1185, 1994.

92. Sampson J, Neaton JD. On being poor with HIV (Commentary). Lancet 344:1100-1101, 1994.

93. Stamler J, Stamler R, Brown WV, Gotto AM, Greenland P, Grundy S, Hegsted DM, Luepker R, Neaton JD, et al. Doing the right thing: stop worrying about cholesterol (Letter to Editor) Circulation 90:2572-2577, 1994.

94. Prineas RJ, Grimm R, Grandits G, Liebson P, Neaton JD, Stamler J, et al. The effect of dietary sodium and body weight on echocardiographic measure of left ventricular mass among treated hypertensive men and women: four year change in the TOMHS Study. Nieren- und Hochdruckkrankheiten 23 (Suppl 1):S14-S21, 1994.

95. Neaton JD, Kuller L, Stamler J, Wentworth DN. Impact of systolic and diastolic blood pressure on cardiovascular mortality. Chapter 9, In Hypertension: Pathophysiology, Diagnosis, and Management. Editors Laragh J, Brennen BM, Raven Press, New York, NY, 1995.

96. Liebson PR, Grandits G, Dianzumba S, Prineas RJ, Grimm RH, Neaton JD, Stamler J. Comparison of five antihypertensive monotherapies and placebo for change in left ventricular mass in patients receiving nutritional-hygiene therapy in the Treatment of Mild Hypertension Study (TOMHS). Circulation 91:698-706, 1995.

97. Chan I, Neaton JD, Saravolatz L, Crane L, Osterberger, J. Frequency of opportunistic events prior to death among HIV infected patients. AIDS 9:1145-1151, 1995.

98. Flack JM, Neaton JD, Grimm RH, Shih J, Cutler J, et al. Blood pressure and mortality among men with a history of myocardial infarction. Circulation 92:2437-2445, 1995.

99. Fleming TR, Neaton JD, Goldman A, DeMets DL, et al. Insights from monitoring the CPCRA didanosine/zalcitabine trial. JAIDS 10:(Suppl 2):S9-S18, 1995.

100. Elmer PJ, Grimm R, Laing B, Grandits G, Svendsen K, Van Heel N, Betz E, Raines J, Link M, Stamler J, Neaton J. Lifestyle intervention results of the Treatment of Mild Hypertension Study (TOMHS) Preventive Medicine 24:378-388, 1995.

101. Neaton JD, Wentworth DN. Considerations in specifying the duration of followup of antiretroviral trials. Medecine Biologie Environment 23(2):171-179, 1995.

102. Klag MJ, Whelton PK, Randall BL, Neaton JD, et al. Blood pressure and incidence of end-stage renal disease in men. N Engl J Med 334:13-18, 1996.

103. Coughlin SS, Neaton JD, Sengupta A. Cigarette smoking as a predictor of mortality from prostate cancer in 348,874 men screened for the Multiple Risk Factor Intervention Trial Amer J Epid 143:1002-1006, 1996.

104. Saravolatz L, Neaton JD, Sacks L, Deyton L, Rhame F, Sherer R. CD4+ cell count and patterns of mortality among patients infected with the human immunodeficiency virus enrolled in the Community Programs for Clinical Research in AIDS (CPCRA). Clin Inf Dis 22:513-520, 1996.

105. Davey Smith G, Neaton JD, Wentworth DN, Stamler R, Stamler J. Socioeconomic differentials in mortality risk among men screened for the Multiple Risk Factor Intervention Trial: Part I - White men Am. J. Pub. Health 86:46-496, 1996.

106. Davey Smith G, Wentworth DN, Neaton JD, Stamler R, Stamler J. Socioeconomic differentials in mortality risk among men screened for the Multiple Risk Factor Intervention Trial: Part II - Black men Am. J. Pub. Health 86:497-504, 1996.

107. Grimm RH, Flack JM, Grandits GA, Elmer PJ, Neaton JD, Cutler JA, et al. Long-term effects on plasma lipids of diet and drugs to treat hypertension: results of the Treatment of Mild Hypertension Study (TOMHS). JAMA 275:1549-1556, 1996.

108. Neaton J. How does one measure change in chronic disease? In Encounters in Glaucoma Research 3. How to Ascertain Progression and Outcome. Editors Anderson DR, Drance SM, Kugler Publications, New York, NY, 1996.

109. The Keystone National Policy Dialogue on Establishment of Studies to Optimize Medical Management of HIV Infection. The Keystone Center, July, 1996.

110. The MRFIT Research Group. Mortality after 16 years for participants randomized to the Multiple Risk Factor Intervention Trial. Circulation 94:946-951, 1996.

111. Stamler J, Stamler R, Garside D, Greenlund K, Archer S, Neaton JD, Wentworth DN. Socioeconomic status, cardiovascular risk factors, and cardiovascular disease: findings on U.S. working populations. In: Report of the Conference on Socioeconomic Status and Cardiovascular Health and Disease, National Institutes of Health, National Heart, Lung, and Blood Institute, November, pp. 109-118, 1996.

112. Larntz K, Neaton JD, Wentworth DN, Yurik T. Data analysis issues for protocols with overlapping enrollment. Stat Med 15:2445-2453, 1996.

113. Burns DN, Hillman D, Neaton JD, Sherer R, et al. Cigarette smoking, bacterial pneumonia and other clinical outcomes in human immunodeficiency virus type 1 infection. JAIDS 13:374-383, 1996.

114. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J. End stage renal disease in African-American and white men: 16-year MRFIT findings. JAMA 277:1293-1298, 1997.

115. El-Sadr W, Neaton JD. Wanted! A simple and meaningful HIV staging system. AJPH 87:546-548, 1997.

116. Coughlin SS, Neaton JD, Randall B, Sengupta A. Predictors of mortality from kidney cancer in 332,547 men screened for the Multiple Risk Factor Intervention Trial. Cancer 79:2171-2177, 1997.

117. Neaton JD, Wentworth DN. Low serum cholesterol and risk of death from AIDS. AIDS 11:929-930, 1997.

118. Brancati F, Whelton PK, Randall BL, Neaton JD, Stamler J, Klag MJ. End stage renal disease risk in diabetes mellitus: a prospective cohort study of 332,544 men screened for MRFIT. JAMA 278:2069-2074, 1997.

119. Torres RA, Neaton JD, Wentworth DN, Abrams D, Sherer R, Ward T, Sampson J. Acyclovir and survival among human immunodeficiency virus-infected patients with CD4 cell counts <500/mm^3. Clin Inf Dis 26:85-90, 1998.

120. Neaton JD. Fundamentals of Clinical Trials (3rd edition). (Book Review). Cont Clinical Trials 19:50-52, 1998.

121. Davey Smith G, Neaton JD, Wentworth DN, Stamler R, Stamler J. Mortality differences between black and white men in the USA: the contribution of income and other factors among men screened for the MRFIT. Lancet 351:934-939, 1998.

122. Lund EM, James KM, Neaton JD. Veterinary randomized clinical trial reporting: a review of the literature. J Vet Internal Med 12:57-60, 1998.

123. Vaccaro O, Stamler J, Neaton JD. 16-year coronary mortality in black and white men with diabetes screened for the Multiple Risk Factor Intervention Trial (MRFIT). Int J Epid 27:636-641, 1998.

124. Stamler J, Greenland P, Neaton JD. The established major risk factors underlying epidemic coronary and cardiovascular disease. CVD Prevention 1:82-97, 1998.

125. Albert JM, Ioannidis JPA, Reichelderfer P, Conway B, Coombs RW, Crane L, et al. Statistical issues for HIV surrogate endpoints: point/counterpoint. Stat Med 17:2435-2462, 1998.

126 Black HR, Elliot WJ, Neaton JD, Grandits G, Grambsch P, et al. Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial Cont Clin Trials 19:370-390, 1998.

127. Capps L, Peng G, Doyle M, El-Sadr W, Neaton JD. Sexually transmitted infections in women with the human immunodeficiency virus Sexually Transmitted Diseases 25:443-447, 1998.

128. Connett J, Neaton JD. Response to: Clinical trials and treatment effects monitoring. Cont Clin Trials 19:525-526, 1998.

129. Green LA, Rhame F, Price RW, Capps L, Sampson J, Deyton L, Schnittman S, Fisher E, Perlman D, Bartsch GE, Krum E, Neaton JD. Experience with a cross-study endpoint review committee for AIDS clinical trials. AIDS 12:1983-1990, 1998.

130. Vazquez JA, Sobel JD, Peng G, Schuman P, Steele-Moore L, Holloway W, Neaton J. Evolution of vaginal candida species recovered from HIV-infected women receiving fluconazole prophylaxis: the emergence of candida glabrata? Clin Inf Dis 28:1025-1031, 1999.

131. Prospective Studies Collaboration. Collaborative overview ('meta-anlaysis') of prospective observational studies of the associations of usual blood pressure and usual cholesterol levels with

common causes of death: protocol for the second cycle of the Prospective Studies Collaboration. J Cardiovasc Risk 6:315-320, 1999.

132. Pitt B, Poole-Wilson P, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger G, Neaton J, Sharma D, Thiyagarajan B. Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design and population baseline characteristics of the Losartan Heart Failure Survival Study - ELITE II J Cardiac Failure 5:146-154, 1999.

133. Stamler J, Stamler R, Neaton JD, Wentworth D, Daviglus ML, Garside DB, Dyer AR, Liu K Greenland P. Low risk-factor profile and long-term cardiovascular and noncardiovascular rmortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA 282:2012-2018, 1999.

134. Eberly LE, Ohman PA, Neaton JD, Price RW, Abrams DI. Kaposi's Sarcoma and CNS Disease: a real association or an artifact of the control group? AIDS 14:995-1000, 2000.

135. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, et al. A randomized study of the short-term effects of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 14:F83-F92, 2000.

136. Stamler J, Daviglus, Garside D, Dyer AR, Greenland P, Neaton JD. Relationship of baseline serum cholesterol in three large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality, and to longevity. JAMA 284:311-318,2000.

137. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm JA, Konstam MA, Riegeger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B. Randomised trial of losartan versus captopril on mortality in patients with symptomatic heart failure: the Losartan Heart Failure Study - ELITE II. Lancet 355:1582-1587, 2000.

138. Winters MA, Baxter JD, Mayers DL, Wentworth DN, Hoover ML, Neaton JD, Merigan TC. Frequency of antiretroviral drug resistance mutations in HIV-1 strains from patients failing triple drug regimens. Anitviral Res 5:57-63, 2000.

139. HIV Surrogate Marker Collaborative Group. Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate endpoints: a meta-analysis. AIDS Res and Human Retro 16:1123-1133, 2000.

140. Centers for Disease Control and Prevention. MMWR. Targeted tuberculin testing and treatment of latent tuberculosis infection. June 9, 2000, Vol. 49, No. RR-6.

141. Pitt B, Williams G, Remme W, Martinez, Lopez-Sendon, Maggioni A, Zannad F, Neaton J, Roniker B, Hurley S, Burns D, Bittman R, Kleiman J. The EPHESUS Trial: Eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Cardiovas Drugs and Therapy 15:79-87, 2001.

142. Black HR, Elliott WJ, Neaton JD, Grandits G, et al. Baseline characteristics and early blood pressure control in the CONVINCE Trial. Hypertension 37:12-18,2001.

143. Emery S, Lane HC, Neaton JD. Letter to the Editor. J Inf Dis 183:680, 2001.

144. Elliott WJ, Black HR, Neaton JD, Grandits G, Fakouhi D. The Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial. Chapter 21, In Clinical Trials in Hypertension. Editor: Black HR, Marcell Dekker, Inc. 2001.

145. Vazquez JA, Peng G, Sobel JD, Steele-Moore L, Schuman P, Holloway W, Neaton JD. Evolution of antifungal susceptibility among *Candida* species recovered from HIV-infected women receiving fluconazole prophylaxis. Clin Inf Dis 33:1069-1075, 2001.

146. Jacob F, Polzin DJ, Osborne CA, Allen TA, Kirk C, Neaton JD, Lekcharoensuk C, Swanson LL. Clinical evaluation of dietary modification for treatment of spontaneous chronic renal failure in dogs. Amer Vet Med Assoc 220: 1163-1170, 2002.

147. Emery S, Abrams DI, Cooper DA, Darbyshire JH, Duncan WR, Lane HC, Lundgren J, Neaton JD. Evaluation of subcutaneous Proleukin (iinterleukin-2) in a randomized international trial: rationale, design and methods of ESPRIT. Cont Clin Trials 23:198-220, 2002.

148. Baxter JD, Merigan TC, Wentworth DN, Neaton JD, et al. Both baseline drug resistance and antiretroviral drug levels are associated with short-term virologic responses to subsequent drug regimens. AIDS 16:1-8, 2002.

149. Domanski M, Pfeffer M, Neaton J, Norman J, et al. Pulse pressure and cardiovascular mortality: 16-year findings on 342,815 men screened for the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 287:2677-2683, 2002.

150. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: one million adults in 61 prospective studies. Lancet 360:1903-1913, 2002.

151. Jacob F, Polzin DJ, Osborne CA, Neaton JD, Lekcharoensuk C, et al. Association between initial systolic blood pressure and risk of developing a uremic crisis or dying in dogs with chronic renal failure. J Amer Vet Med Assoc 222:322-329, 2003.

152. Eberly LE, Stamler J, Neaton JD. Relation of triglycerides, fasting and non-fasting, to coronary heart disease mortality. Arch Int Med 163:1077-1083, 2003.

153. Black HR, Elliott Wj, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm RH et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial. JAMA 289:2073-2082, 2003.

154. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309-1321, 2003.

155. Lane HC, Neaton JD. When to start therapy for HIV infection: a swinging pendulum in search of data. Annals Intern Med 138:680-681, 2003.

156. Greenland P, Knoll MD, Stamler J, Neaton JD, et al. Major risk factors are nearly universal antecedents of clinical coronary heart disease in three large U.S. cohorts. JAMA 290:891-897, 2003.

157. Reisler RB. Han C, Burman WJ, Tedaldi EM, Neaton JD. Beginning to weigh the long term risks: incidence of grade 4 events, AIDS, and mortality in a large multicenter cohort receiving HAART. JAIDS 34:379-386, 2003.

158. Perez G, MacArthur RD, Walmsley S, Baxter J, Mullin C, Neaton JD. A randomized clinical trial comparing nelfinavir and ritonavir in patients with advanced HIV disease (CPCRA 042/CTN 102). HIV Clinical Trials 5:7-18, 2004.

159. Kuller LH, Thomas A, Grandits G, Neaton JD for the MRFIT Research Group. Elevated prostate-specific antigen (PSA) levels up to 25 years prior to death from prostate cancer. Cancer Epidemiol Biomarkers Prev 13:373-377, 2004.

160. Eberly LE, Neaton JD, Thomas A, Dai Y. Multiple-stage screening and mortality for the Multiple Risk Factor Intervention Trial. Clinical Trials 1:148-161, 2004.

161. DeMets DL, Califf R, Dixon D, Fleming T, Ellenberg S, Freidman L, Held P, Julian D, Kaplan R, Levine R, Neaton J, Packer M, Pocock S, Rockhold F, Seto B, Siegel J, Snapinn S, Stump D, Temple R, Whitley R. Issues in regulatory guidelines for data monitoring committees. Clinical Trials 1:161-169, 2004.

162. Vaccaro O, Eberly LE, Neaton JD, Yang L, Riccardi G, Stamler J. Impact of diabetes and previous myocardial infarction on long-term survival - 25 year mortality follow-up of primary screenees of the Multiple Risk Factor Intervention Trial. Archives Int Med 164:1438-1443, 2004.

163. Arduino RC, Nannini EC, Rodriguez-Barradas M, Schrader S, Losso M, Ruxrungtham K, Allende M, Emery S, Fosdick L, Neaton JD, Tavel J, Davey R, Lane HC. CD4 cell response to three doses of subcutaneous interleukin-2: meta-analysis of three Vanguard studies. J Inf Dis 39:115-122, 2004.

164. Neaton JD. Quantitative Science. In: Mayer K, Pizer H (eds.). The AIDS Pandemic. Impact on Science and Society. Elsevier Academic Press, 2005.

165. Jacob F, Polzin DJ, Osborne CA, Neaton JD, Kirk CA, et al. Evaluation of the association between initial proteinuria and morbidity rate or death in dogs with naturally occurring chronic renal failure. J Amer Vet Med Assoc 226:393-400, 2005.

166. Davey Smith G, Shaten J, Svendsen K, Neaton JD, Haffner SM, Kuller LH. Incidence of type II diabetes in the randomized Multiple Risk Factor Intervention Trial. Annals Int Med 142:313-322, 2005.

167. Neaton JD, Kuller LH. Diuretics are color blind (editorial). JAMA 293:1663-1666, 2005.

168. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, Neaton JD, et al. Results of the Controlled ONset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE) Trial by Geographical Region. J Hypertension 23:1099-1106, 2005.

169. Normand SLT, Rector TS, Neaton JD, Pina IL, Lazar R, et al. Clinical and analytic considerations in the study of health status in device trials for heart failure. J Card Fail 11:396-403, 2005.

170. Stamler J, Neaton JD, Garside DB, Daviglus ML. Current status: six established major risk factors – and low risk. In: Marmot MG, Elliott P (eds) Coronary Heart Disease Epidemiology: From Aetiology to Public Health, Oxford University Press, June 2005.

171. Thomas AJ, Eberly LE, Davey Smith G, Neaton JD, Stamler J. Race/ethnicity, income, major risk factors and CVD mortality AJPH 95:1417-1423, 2005.

172. Konstam MA, Neaton JD, Poole-Wilson PA, Pitt B, et al. Comparison of losartan and captopril on heart failure - related outcomes and symptomatology from the Losartan Heart Failure Survival Study (ELITE II). Amer Heart J 150:123-131, 2005.

173. Zhao Y, Grambsch PM, Neaton JD. Comparison of numerical algorithms for bivariate sequential tests based on marginal criteria. Comp Stat and Data Anal 49:631-641, 2005.

174. Thomas AJ, Eberly LE, Neaton JD, Davey Smith G. Latino risk- and income-adjusted mortality in the men screened for the Multiple Risk Factor Intervention Trial (MRFIT) Amer J Epidemiol 162:569-578, 2005.

175. Loutfy MR, Walmsley SL, Mullin CM, Perez G, Neaton JD. CD4+ predicts clinical benefit in patients with advanced HIV with persistent viremia after one year of combination antiretroviral therapy. JID 192:1407-1411, 2005.

176. Neaton JD, Gray G, Zuckerman BD, Konstam MA. Key issues in endpoint selection for heart failure trials: composite endpoints. J Card Fail 11:567-575, 2005.

177. MacArthur R, Perez G, Walmsley S, Baxter J, Mullin CM, Neaton JD. Comparison of CD4 cell count and HIV RNA level for short- and long-term risk of disease progression in patients with advanced HIV infection on highly active antiretroviral therapy. HIV Clinical Trials 6:127-135, 2005.

178. Neaton JD. Safeguards in studies: the role of data monitoring committees in clinical trials. Chance 18:55-58, 2005.

179. Neaton JD, Wentworth DN, Jacobson MA. Data monitoring experience in the TOXO Study (CPCRA 001). In: DeMets DL, Freidman L, Furberg C (eds.) Data Monitoring in Clinical Trials. A Case Studies Approach, Springer-Verlag, 2006.

180. Eberly LE, Prineas R, Cohen J, Vazquez G, Zhi X, Neaton JD, Kuller LW. Metabolic syndrome: risk factor distribution and 18-year mortality in the Multiple Risk Factor Intervention Trial Diabetes Care) 29:123-130, 2006.

181. Duran AS, Ivalo SA, Hakim A, Masciottra MF, Zlatkes R, Adissi L, Neaton JD, Losso M. Prevention of mother-to-child HIV transmission. Medicina (Buenos Aires) 66:24-30, 2006.

182. Ishani A, Grandits, G, Grimm RH, Prineas RS, Neaton JD. Association of single measurements of dipstick proteinuria, estimated glomular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the Multiple Risk Factor Intervention Trial J Amer Soc Nephrol 17:1444-1452, 2006.

183. Mocroft A, Neaton J, Bebchuk J, Staszewski S, Antunes A, Knysz B, Law M, Phillips AN, Lundgren J. The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era. Clinical Trials 14:119-132, 2006.

184. Neaton JD, Mugglin AS. From observational studies to randomized trials: asking the right question at the right time. J Clin Periodontol 33:517-519, 2006.

185. Stamler J, Neaton J, Garside DB, Davigulus ML. The major adult cardiovascular diseases: a global historical perspective. In: Lauer R, Burns TL, Daniels S (eds.). Pediatric Prevention of Atherosclerotic Cardiovascular Disease. Oxford University Press, 2006.

186. Stamler J, Davigulus ML, Garside DB, Greenland P, Eberly LE, Yang L, Neaton JD. Low risk cardiovascular status: impact on cardiovascular mortality and longevity. In: Lauer R, Burns TL, Daniels S (eds.). Pediatric Prevention of Atherosclerotic Cardiovascular Disease. Oxford University Press, 2006.

187. Thomas A, Eberly L, Neaton JD, Davey-Smith G. ZIP-code based versus tract-based income measures as long-term risk-adjusted mortality predictors. Amer J Epid 164:586-590, 2006.

188. Terry PD, Abramson JL, Neaton JD. Blood pressure and risk of death from external causes in men screened for MRFIT Amer J Epid DOI: 10.1093/aje/kwk014, 2006.

189. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count - guided interruption of antiretroviral treatment. N Engl J Med 355:2283-2296, 2006.

190. Neaton JD, Design of Outcome Studies. In Hypertension: A Companion Text to Braunwald's Heart Disease, First Edition, EEds. Black HR, Elliott WJ, W.B. Saunders, 2006.

191. Neaton JD, Normand SL, Gelijns A, et al. Designs for mechanical circulatory support device studies. J Card Fail 13:63-74, 2007.

192. The ESPRIT Research Group. Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count ≥ 300 cells/μL who were assigned to 7.5 MIU interleukin-2. HIV Medicine 8:112-123, 2007.

193. Zhao Y, Grambsch PM, Neaton JD. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome Clinical Trials 4:140-153, 2007.

194. Thomas AJ, Eberly LE, Neaton JD, Davey Smith G. Census-based and personally reported income measures as long-term risk-adjusted mortality predictors. Public Health 121:898-901, 2007.

195. Silverberg, MJ, Neuhaus J, Bower M, Gey D, Hatzakis A, Henry K, Hidalgo J, Lourtau L, Neaton JD, Tambussi G, Abrams DI. Risk of cancers during interrupted antiretroviral therapy in the SMART Study AIDS 21:1957-1963, 2007.

196. Reekie J, Mocroft A, Neaton JD, Lundgren. Clinical endpoints in clinical trials of anti-HIV treatment. Future HIV Ther 1:251-258, 2007.

197. Kuller LH, Grandits G, Cohen JD, Neaton JD, Prineas R. Lipoprotein particles, insulin, adiponectin, C-reactive protein and risk of coronary heart disease among men with the metabolic syndrome. Atherosclerosis 195:122-128, 2007.

198. Greenberg B, Czerka B, Abraham WT, Neaton JD, et al. Rationale, design, and methods for a pivotal randomized clinical trial of continuous aortic flow augmentation in patients with exacerbation of heart failure: Multi-center trial of the Orquis® Medical Cancion® System for the Enhanced Treatment of Heart Failure Unresponsive to Medical Therapy (MOMENTUM). J Card Fail 13:715-721, 2007.

199. Prospective Studies Collaboration. Blood cholesterol and vascular mortality by age, sex and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370:1829-1839, 2007.

200. Neaton JD, Grund B. Earlier initiation of antiretroviral therapy in treatment naive patients: implications of results of treatment interruption trials. Curr Opin HIV AIDS 3:112-117, 2008.

201. Neaton JD, Lane HC. Getting personal about treating HIV. Nat Med (editorial) 4:369-370, 2008.

202. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Inferior clinical outcome of the CD4+ count guided antiretroviral treatment interruption strategy in SMART: Role of CD4+ Counts and HIV-RNA levels during follow-up JID 197:1145-1155, 2008.

203. Baker JV, Peng G, Rapkin J, Abrams D, Silverberg MJ, MacArthur RD, Cavert WP, Henry WK, Neaton JD. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection AIDS 22:841-848, 2008.

204. Adabag AS, Grandits G, Prineas RJ, Crow RS, Bloomfield HE, Neaton JD. Assessment of exercise heart rate parameters for predicting mortality and sudden death Amer J Cardiol 101:1437-1443, 2008.

205. Krishnan E, Svendsen KH, Neaton JD, Grandits GA, Kuller LH. Long-term cardiovascular mortality among middle-aged men with gout Arch Intern Med 168:1104-1110, 2008.

206. Baker JV, Peng G, Rapkin J, Krason D, Reilly C, Cavert WP, Abrams D, MacArthur RD, Henry WK, Neaton JD. Poor initial CD4+ recovery with antiretroviral therapy prolongs immune depletion and increases risk of AIDS and non-AIDS diseases. JAIDS 48: 541-546, 2008.

207. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. Clinical outcomes in the SMART study after recommendation to re-initiate antiretroviral therapy for participants randomized to the CD4+ guided interruption strategy. Ann Intern Med 149:289-299, 2008.

208. The SMART/INSIGHT and the D:A:D Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the SMART Study AIDS 22:F17-F24, 2008.

209. Eberly L, Stamler, J, Kuller LH, Neaton JD. Multiple Risk Factor Intervention Trial (MRFIT). Encyclopedia of Clinical Trials, Eds. D"Agostino, RB, Sullivan L, Massaro J, John Wiley & Son, Inc., 2008, doi: 10.1002/9780471462422.eoct628.

210. Konstam MA, Poole-Wilson PA, Dickstein K, Drexler H, Justice SJ, Komajda M, Malbecq W, Martinez FA, Neaton JD, Riegger GA, Guptha S. Design of the heart failure endpoint evaluation of all-antagonist losartan (HEAAL) study in patients tolerant to an ACE-inhibitor. Euro J Heart Fail 10:899-906, 2008.

211. Greenberg B, Czerka B, Delgado RM, Bourge, R, Zile, MR, Silver M, Klapholz M, Haeusslein E, Mather P, Abraham WT, Neaton JD, Brown S, Parker IC, Konstam MA. Effects of continuous aortic flow augmentation in patients with exacerbations of heart failure, inadequately responsive to medical therapy: results of the multi-center trial of the Orquis® medical cancion® system for enhanced treatment of heart failure unresponsive to medical therapy (MOMENTUM) Circulation 118:12411-1249, 2008.

212. Stamler J, Neaton JD. The Multiple Risk Factor Intervention Trial (MRFIT) – Importance then and now. JAMA 300:1344-1347, 2008.

213. Kuller LH, Tracy R, Belloso W, DeWit S, Drummond F, Lane HC, Ldergerber B, Lundgren J, Neuhaus J, Nixon D, Paton NI, Neaton JD. Activation of inflammatory and coagulation pathways is associated with mortality in patients with HIV infection. PLoS Medicine 5:e203, 2008.

214. Phillips AN, Neaton J, Lundgren J. The role of HIV in serious diseases other than AIDS. AIDS 22:2409-2418, 2008.

215. Neaton JD. Renal outcomes in SMART (Letter to the Editor). Ann Intern Med 150:282, 2009.

216. Neaton JD. Quality Assurance: Prevention of Missing Data. In Successful Randomized Clinical Trials – A Handbook for the 21st Century. Editors: Michael Domanski and Sonja McKinlay, Lippincott Williams & Wilkins, 2009.

217. Lundgren JD, Phillips AN, Neaton JD. Uncertainty of whether antiretroviral therapy has favourable risk:benefit ratio in recently HIV-infected people (Letter to the Editor) CID 48:1162, 2009.

218. Baker JV, Henry K, Neaton JD. The consequences of HIV infection and antiretroviral therapy use for cardiovascular disease risk: shifting paridigms. Curr Opinion in HIV and AIDS 4:176-182, 2009.

219. Duprez DA, Kuller LH, Tracy R, Otvos J, Cooper D, Hoy J, Neuhaus J, Paton NI, Friis-Moler N, Liappis A, Neaton JD. Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis 207:524-529, 2009.

220. Baker JV, Duprez D, Rapkin J, Grimm R, Neaton JD, Henry K. Untreated HIV infection and large and small artery elasticity. JAIDS 52:25-31, 2009.

221. INSIGHT ESPRIT Study Group and SILCAAT Scientific Committee. Interleukin-2 therapy in patients with HIV infection. N Engl J Med 361:1548-1559, 2009.

222. Konstam MA, Neaton JD, Dickstein K, Drexler H, Komajda M, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomized, double-blind trial. Lancet 374:1840-1848, 2009.

223. Baker JV, Woubeshet A, Quick H, Huppler-Hullsiek K, Tracy R, Henry K, Duprez D, Neaton JD. High-density lipoprotein particles and marker of inflammation and thrombotic activity in patients with untreated HIV infection. JID 201:285-292, 2010.

224. Neuhaus J, Jacobs DR, Jr., Baker JV, Calmy A, Duprez D, LaRosa A, Kuller LH, Pett S, Ritsola M, Ross MJ, Shlipak MG, Tracy R, Neaton JD. Markers of Inflammation, coagulation and renal function are elevated in adults with HIV infection. JID 201:1788-1795, 2010.

225. Baker JV, Quick H, Huppler Hullsiek K, Tracy R, Duprez D, Henry K, Neaton JD. IL-6 and D-dimer levels are associated with vascular dysfunction in patients with untreated HIV infection. HIV Medicine Epub DOI:1111;j.1468-1293.2010.00835.x, 2010.

226. Achhra AC, Amin J, Law MG, Emery S, Gerstoft J, Gordin F, Vjecha M, Neaton JD, Cooper DA. Immunodeficieny and the risk of serious clinical endpoints in a well-studied cohort of treated HIV-infected patients. AIDS 24:1877-1886, 2010.

227. Phidisa II Writing Team for Project Phidisa. A randomized factorial trial comparing 4 treatment regimens in treatment-naïve HIV-infected persons with AIDS and/or < 200 CD4+ cells/μL in South Africa. JID 202:1529-1537, 2010.

228. Neaton JD, Babiker A, Bohnhorst M, Darbyshire J, Denning E, et al. Regulatory impediments jeopardizing the conduct of clinical trials in Europe funded by the National Institutes of Health Clinical Trials 7:705-718, 2010.

229. Neaton JD, Neuhaus J, Emery S. Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997-2010. Current Opinion HIV and AIDS 5:480-490, 2010.

230. Soliman E, Prineas RJ, Roediger M, Duprez DA, Boccara F, Boesecke C, Stephan C, Hodder S, Stein JH, Lundgren JD, Neaton JD. Prevalence and prognostic significance of ECG abnormalities in HIV-infected patients: Results from the Strategies for Management of Antiretroviral Therapy (SMART) study. J Electrocardiography 44:779-785, 2011.

231. Panel on Handling Missing Data in Clinical Trials. National Research Council (2010). The prevention and treatment of missing data in clinical trials. Committee on National Statistics. Division of Behavioral and Social Sciences and Education. Washington D.C.: The National Academies Press.

232. Soliman EZ, Lundgren JD, Roediger MP, Duprez DA, Temesgen Z, Bickel M, Schlay JC, Somboonwit C, Reiss P, Stein JH, Neaton JD. Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations in the Strategies for Management of Antiretroviral Therapy (SMART) Trial. AIDS 25:367-377, 2011.

233. Baker JV, Neuhaus J, Duprez D, Kuller lH, Tracy R, Belloso WH, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Nixon DE, Paton NI, Neaton JD. Changes in inflammatory and coagulation biomarkers: a randomized comparison or immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Defic Syndr 56:36-43, 2011.

234. Gezmu M, DeGruttola V, Dixon D, Essex M, Halloran E, Hogan J, Grobler A, Kim S, McDermott J, McKaig R, Neaton JD. Strengthening biostatistics resources in Sub-Saharan Africa: research considerations through U.S. partnerships. Stat Med 30: 695-708, 2011.

235. Duprez DA, Neuhaus J, Tracy R, Kuller LH, Deeks SG, Orkin C, Stoehr A, Woolley IJ, Neaton JD. N-terminal-proB-type peptide (NT-proBNP) predicts cardiovascular disease events in HIV-infected patients: results of the SMART study. AIDS 203:651-657, 2011.

236. Sandler NS, Wand H, Roque AP, Law M, Nason M, Nixon DF, Pederson C, Ruxrungtham K, Lewin S, Emery S, Neaton JD, Brenchley JM, Deeks SG, Sereti I, Douek DC. Plasma levels of soluble CD14 independently predict mortality in HIV infection. JID 203:780-790, 2011.

237. Gansevoort RT, Matsushiuta K, and the Chronic Kidney Disease Prognosis Consortium. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes in both general and high-risk poulations. A collaborative meta-analysis of general and high-risk population cohorts. Kidney Int 80:93-104, 2011.

238. van der Velde M, Matsuhita K, Coresh J et al and the Chronic Kidney Disease Prognosis Consortium. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause mortality and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 79:1331-1340, 2011.

239. Boulware DR, Huppler Hullsiek K, Puronen CE, Rupert A, Baker JV, French MA, Bohjanen PR, Novak RM, Neaton JD, Sereti I. Higher levels of CRP, D-dimer, IL-6 and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with an increased risk of AIDS or death. JID 203:1637-1646, 2011.

240. Program to Improve Life and Longevity (PILL) Collaborative Group. An international randomised placebo-controlled trial of a four-component combination pill ("polypill") in people with raised cardiovascular risk PLoS One 6:e19857. Doi: 10.1371, 2011.

241. Morrison BW, Cochran CJ, White JG, Harley J, Kleppinger CF, Liu A, Mitchel JT, Nickerson DF, Zacharias CR, Kramer JM, Neaton JD. Monitoring the quality of conduct of clinical trials: a survey of current practices. Clinical Trials 8:342-349, 2011.

242. INSIGHT Influenza Study Group. Surveillance of illness associated with pandemic (H1N1) 2009 virus infection among adults using a global clinical site network approach: the INSIGHT FLU 002/FLU 003 Studies. Vaccine 295:B56-B62, 2011.

243. Baker JV, Neuhaus J, Duprez D, Cooper DA, Hoy J, Kuller L, Lampe F, Liappis A, Friis-Moller N, Otvos J, Paton NI, Tracy R, Neaton JD. Inflammation predicts changes in high-density lipoprotein particles and apolipoprotein A1 following initiation of antiretroviral therapy. AIDS 25:2133-2142, 2011.

244. Ernst ME, Neaton JD, Grimm RH Jr., Collins G, et al. Long-term effects of chlorthalidone vs hydrochlorothiazide on electrocardiographic left ventricular hypertrophy in the Multiple Risk Factor Intervention Trial. Hypertension 58:1001-1007, 2011.

245. Baker JV, Neuhaus J, Duprez D, Freiberg M, Barnardino JI, Badley A, Nixon D, Lundgren J, Tracy R, Neaton JD. HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunction. J Acquir Immune Defic Syndr 60:128-134, 2012.

246. Ledwaba L, Tavel J, Khabo P, Maja P, Quin J, Sangweni P, Liu X, Follmann D, Metcalf JA, Orsega S, Baseler B, Neaton JD, Lane HC. Pre-ART levels of inflammation and coagulation markers are strong predictors of death in a South African cohort with advanced HIV disease. PLoS One 7; e24243, 2012

247. Mulrooney DA, Ness KK, Solovey A, Hebbel RP, Neaton JD, Peterson BA, Lee CK, Kelly AS, Neglia JP. Pilot study of vascular health in survivors of Hodgkin lymphoma. Pediatr Blood Cancer 59:285-289, 2012.

248. Matsushita K, Mahmoodi BK, Woodward M, et al. Comparison of risk prediction using the CKD-EPI equation and MDRD Study equation for estimated glomerular filtration rate. JAMA 307:1941-1951, 2012.

249. Little RJ, Cohen ML, Dickersin K, Emerson SS, Farrar JT, Neaton JD, Shih W, Siegel JP, Stern H. The design and conduct of clinical trials to limit missing data. Stat Med 31:3433-3443, 2012.

250. Stamler J, Neaton JD, Cohen J, Cutler J, Eberly, L, Grandits G, Kuller L, Ockene J, Prineas R. Composite coronary and cardiovascular outcomes in the Multiple Risk Factor Intervention Trial (MRFIT) J American Heart Association epub ahead of print doi: 10.1161/JAHA.112.003640. August 2012.

251. Neaton JD, Design of Outcome Studies. In Hypertension: A Companion Text to Braunwald's Heart Disease, Second Edition, EEds. Black HR, Elliott WJ, W.B. Elsevier Saunders, 2012.

252. Duprez DA, Kuller LH, Tracy R, Belloso W, DeWit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Neuhaus J, Nixon D, Paton NI, Prineas RJ, Neaton JD. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One 7:e44454, September 2012.

253. Little RJ, Cohen ML, Dickerson K, Emerson SS, Farrar JT, Molenberghs G, Nurphy SA, Neaton JD, Rotinsky A, Scharfstein D, Shih W, Siegel JP, Stern H. The prevention and treatment of missing data in clinical trials. N Engl J Med 367:1355-1360, 2012.

254. Dawood FZ, Khan F, Roediger MP, Zhang Z, Swaminathan S, Klinker H, Hoy J, Lundgren J, Neaton JD, Soliman EZ. Electrocardiographic spatial QRS-T angle and incident cardiovascular disease in HIV-infected individuals: results from the Strategies for the Management of Antiretorviral Therapy (SMART) study. Am J Cardiol 2012.08.054

255. Baker JV, Huppler Hullsiek K, Prosser R, Duprez D, Grimm R, Tracy RP, Rhame F, Henry K, Neaton JD. Angiontensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for person with HIV infection: a pilot randomized trial. PLoS One 2012.e46894.

256. Kiernan MS, Wentworth D, Francis G, Martinez FA, Dickstein K, Komajda M, Zannad F, Neaton JD, Konstam MA. Predicting adverse events during angiotensin receptor blocker treatment in heart failure: results from the HEAAL trial. Eur J Heart Failure 14:1401-1409, 2012.

257. Lan G, Lindborg S, Neaton J. Panel Discussion 2. University of Pennsylvania Conference on Statistical Issues in Clinical Trials: Emerging statistical issues in the conduct and monitoring of clinical trials. Clin Trials 9:736-740, 2012.

258. Gupta M, Miller CJ, Baker JV, Lazar J, Bogner JR, Calmy A, Soliman EZ, Neaton JD. Biomarkers and electrocardiographic evidence of myocardial ischemia in individuals with HIV infection. Am J Cardiol 2012.11.032.

259. Nitsch D, Grams M, Snag Y, et al for the Chronic Kidney Disease Prognosis Consortium. Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta analysis. BMJ 346:f324.doi 10.1136, 2013.

260. Davey RT, Lynfield R, Dwyer DE, Losso MH, Cozzi-Lepri A, Wenworth D, Lane HC, Dewar R, Rupert A, Metcalf JA, Pett, SL, Uyeki TM, Bruguera JM, Angus B, Cummins N, Lundgren J, Neaton JD. The association between serum biomarkers and disease outcome in influenza A(H1N1) virus infection. PLoS One, Vol 8, Issue 2, e57121, 2013.

261. Soliman EZ, Roediger M, Duprez DA, Knobel H, Elion R, Neaton JD. Protease inhibitors and cardiac autonomic function in HIV-infected patients: a cross-sectional analysis from the Strategies for Management of Antiretroviral Therapy (SMART) Trial. BMJ Open, 3:e002533, 2013.

262. Borges AH, Silverberg MJ, Wentworth D, Grulich A, Fatkenheuer G, Mitsuyasu R, Tambussi G, Sabin C, Neaton JD, Lundgren JD. Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation markers. AIDS 27:1433-1441, 2013.

263. Rotger M, Glass TR, Junier T, Lundgren J, Neaton JD, Poloni ES et al. Contribution of genetic background, traditional risk factors and HIV-related factors to coronary artery disease events in HIV-positive persons. CID 57:112-121, 2013.

264. Mulrooney DA, Ness, KK, Huang S, Solovey A, Hebbel, RP, Neaton JD, et al. Pilot study of vascular health in survivors of osteosarcoma. Pediatr Blood Cancer doi: 10.1002/pbc.24610, 2013.

265. Eberly L, Stamler J, Kuller LH, Neaton JD. Multiple Risk Factor Intervention Trial (MRFIT). Encyclopedia of Statistical Sciences. doi: 10.1002/0471667196.ess7185, 2013.

266. Lundgren JD, Babiker AG, Gordin FM, Borges AH, Neaton JD. When to start antiretroviral therapy: the need for an evidence base during early HIV infection. BMC Medicine 11:148, doi: 10.1186/1741-7015-11-148, 2013.

267. Babiker AG, Emery S, Fatkenheuer G, Gordin FM, Grund B, Lundgren J, Neaton JD, Pett SL, Phillips A, Touloumi G, Vjecha MJ for the INSIGHT START Study Group. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Trial (START) study. Clinical Trials 10: (Suppl 1): S5-S36, 2013.

268. Baker JV, Brummel-Ziedins K, Neuhaus J, Duprez D, Cummins N, Dalmau D, DeHovitz J, Lehman C, Sullivan A, Woolley I, Kuller L, Neaton JD, Tracy RP. HIV replication alters the composition of extrinsic pathway coagulation factors and increases thrombin generation. JAHA 2(4):e000264, 2013.

269. Neaton JD. HIV and cardiovascular disease: comment on Islam et al. (Letter to the Editor) HIV Medicine 14:517-518, 2013.

270. Hatano H, Strain MC, Scherzer R, Bacchetti P, Wentworth D, Hoh R, Martin JN, McCune JM, Neaton JD, Tracy RP, Hsue PY, Richman DD, Deeks SG. Increase in 2-LTR circles and decrease in D-dimer after raltegravir intensification in treated HIV-infected patients: a randomized, placebo-controlled trial. JID 208: 1436-1442, 2013.

271. Zhang J, Carlin BP, Neaton JD, Soon GG, Nie L, Kane R, Virnig BA, Chu H. Towards patient-centered network meta-analysis of randomized clinical trials with binary outcomes: reporting the proper summaries. Clinical Trials Epub ahead of print 3 October 2013.

272. Cummins NW, Neuhaus J, Sainski AM, Strausbauch MA, Wettstein PJ, Lewin SR, Plana M, Rizza SA, Temesgen Z, Touloumi G, Freiberg M, Neaton JD, Badley AD. CD4 T cell declines occurring during suppressive antiretroviral therapy reflect continued production of Casp8p41. AIDS Res Hum Retroviruses Epub ahead of print 17 December 2013.

273. Cobb LK, Anderson CAM, Elliott P, Hu FB, Liu K, Neaton JD, Whelton PK, Woodward M, Appel L. Methodological issues in cohort studies that relate sodium intake and cardiovascular disease outcomes: a scientific advisory from the American Heart Association. Circulation 129:1173-1186, 2014.

274. Sanfilippo KM, McTigue K, Fidler CJ, Neaton JD, Chang Y, Fried LF, Liu S, Kuller LH. Hypertension and obesity and the risk of kidney cancer in two large cohorts of US men and women. Hypertension 63: 934-941, 2014.

275. Miller C, Baker JV, Bormann AM, Erlandson KM, Huppler Hullsiek K, Justice AC, Neuhaus J, Paredes R, Petomenos K, Wentworth D, Winston A Wolfson J, Neaton JD. Adjudicated morbidity and mortality outcomes by age among individuals with HIV infection on suppressive antiretroviral therapy. PLoS One 9(4):e95061. doi:10.1371/journal.pone.0095061, 2014.

276. Peters L, Neuhaus J, Duprez D, Neaton JD, Tracy R, Klein MB, Mocroft A, Rockstroh J, Dore G, Lundgren JD. Biomarkers of inflammation, coagulation and microbial translocation in HIV/hepatitis co-infected patients in the SMART study. J Clin Virology doi: 10.1016/j.jcv.2014.03.017, April 2014.

277. Nordell AD, McKenna M, Borges A, Duprez D, Neuhaus J, Neaton JD. Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation. JAHA doi: 10.1161/JAHA.114.000844, May 2014.

278. Dawood FZ, Roediger M, Grandits G, Miller D, Fisher M, Zhang ZM, Hodder S, Hoy JF, Lundgren JD, Neaton JD, Soliman EZ. Determinants of developing widened spatial QRS-T angle in HIV-infected individuals: results from the Strategies for Management of Antiretroviral Therapy (SMART) Study. (in press J Electrocardiography.

279. Lynfield R, Davey R, Dwyer DE, Losso MH, Wentworth D, Cozzi-Lepri A, Herman-Lamin K, Cholewinska G, David D, Kuetter S, Uyeki TM, Lane HC, Lundgren J, Neaton JD. Outcomes of influenza A(H1N1)pdm09 virus infection: results from two international cohort studies (in press PLoS One).

280. Young LC, Roediger MP, Grandits G, Baker J, Somboonwit C, Williams I, Lundgren JD, Neaton JD, Soliman EZ, for the INSIGHT/SMART Study Group. Relationship between inflammatory and coagulation biomarkers and cardiac autonomic function in HIV–infected individuals. (in press Biomarkers Med).

281. Borges AH, Weitz j, Collins G, Baker JV, Levy Y, Davey RT, Phillips AN, Neaton JD, Lundgren JD, Deeks SG. Markers of inflammation and activation of coagulation are associated with anemia in antiretroviral-treated HIV disease (submitted to AIDS)

282. A Dooko CB, DeWit S, Neuhaus J, Palfreeman A, Pepe R, Pankow J, Neaton JD. Interleukin-6, high sensitivity C-reactive protein, and the development of type 2 diabetes among HIV positive patients taking antiretroviral therapy (submitted to JAIDS).

283. Duprez D, Otvos J, Tracy R, Feingold K, Greenland P, Gross MD, LimA J, Mackey RH, Neaton J, Sanchez OA, Jacobs DR. High density lipoprotein subclasses and interleukin-6 are independent predictors of incident cardiovascular and non-cardiovascular, non-cancer inflammatory-related events: The Multi-Ethnic Study of Atherosclerosis. (submitted to Lancet).

Presentations at Scientific Meetings, NIH/FDA Workshops and Scientific Symposia:

Design, implementation and field experience with the use of computer terminals in clinical centers in the Multiple Risk Factor Intervention Trial, Ninth International Biometric Society Conference, August, 1976, Boston, MA.

The "Oslo-like" cohort in the Multiple Risk Factor Intervention Trial. NHLBI Workshop on Primary Prevention of Coronary Heart Disease: Implications of the MRFIT. February, 1982, Bethesda, MD.

Total and CHD mortality in relation to smoking, serum cholesterol and diastolic blood pressure among Black and White men followed five years, AHA Cardiovascular Epidemiology Conference, March, 1983, San Diego, CA.

MRFIT subgroup findings, Sydenham Society, April 1983, Washington D.C. Do multiple risk factors explain racial differences and CHD mortality trends in Black populations? Symposium on recent Advances in Hypertension and Coronary Heart Disease in Black Populations, October, 1983, Baltimore, MD.

Use of logistic model in the design of intervention studies. Fifth Annual Meeting Society of Clinical Trials, May 1984, Miami, FL.

Monitoring of drug associated adverse reactions in a multiclinic trial. Eighty-ninth Annual Meeting of the American Society for Clinical Pharmacology and therapeutics, March, 1985, San Antonio, Texas.

Recruitment experience in the Multiple Risk Factor Intervention Trial. NIH Workshop on Recruitment of Patients in Cardiovascular Trials, April, 1986. Bethesda, MD.

Estimation of event rates for clinical trials, Spring Meetings of the Biometric Society (ENAR), March, 1988.

An examination of the efficiency of some quality assurance methods commonly employed in clinical trials, NIH Workshop on Cost and Efficiency in Clinical Trials, February, 1989.

Statistical design of the Treatment of Mild Hypertension Study (TOMHS). Tenth Annual Meeting Society of Clinical Trials, May, 1989, Minneapolis, MN.

What do you do when the data don't look right? Panel Discussion. Tenth Annual Meeting Society of Clinical Trials, May, 1989, Minneapolis, MN.

Facilitating critical evaluation of clinical trial reports. Annual Meeting. Council of Biology Editors, May 1989, Rochester, MN.

Comparison of 10 year coronary and cerebrovascular disease mortality rates by hypertensive status for black and white men screened in the MRFIT. American Heart Association, November 1989, New Orleans, Louisiana.

Quality control issues in multicenter clinical trials (Discussant), Society for Clinical Trials, May, 1990, Toronto, Canada.

Low serum cholesterol: risk of disease and determinants. NIH Workshop on Low Blood Cholesterol Levels and Disease, October, 1990, Bethesda, MD.

Lessons from Epidemiological Studies on the Prevention of Cardiovascular Disease, 5th Annual Meeting of Spanish Society of Preventive Cardiology, April, 1991, Jaca, Spain.

Long-term follow-up results of MRFIT, 5th Annual Meeting of Spanish Society of Preventive Cardiology, April, 1991, Jaca, Spain.

Issues in the design and conduct of AIDS trials. FDA Conference on the Role of Alternative Data Sources in AIDS Drug Development, May, 1991, Rockville, MD.

Ethnicity and renal disease: lessons from MRFIT and TOMHS. NIH Workshop on the Biology of Kidney Disease and Hypertension in Blacks, Washington D.C., December, 1991.

The challenges and opportunities of large, simple, community-based clinical trials: Four perspectives, organizer/chair of invited session, Biometric Society (ENAR),March, 1992, Cincinnati, Ohio.

Relative efficiency of taking research to the patient versus the patient to research, 13th Annual Meeting for Society for Clinical Trials, May, 1992, Philadelphia, PA.

Determinants of death from stroke. NIH Workshop on the Decline in Stroke Mortality, November 1992, Bethesda, MD.

Overview of toxoplasma prophylaxis studies. International Consensus Conference on Toxoplasma Prophylaxis, June, 1993, Berlin, Germany.

Is disease progression the optimal endpoint for AIDS Clinical Trials? IXth International Conference on AIDS, June 1993, Berlin, Germany.

Considerations in choice of a clinical endpoint for AIDS clinical trials. Societal Institute of the Mathematical Sciences 1993 AIDS Conference, June 1993, Blaubeuren, Germany.

What is going on at the lower end of the blood cholesterol distribution? 3rd International Conference on Preventive Cardiology, June 1993, Oslo, Norway.

Statistical design considerations for a large, simple trial (LST) on timing of combination nucleoside treatment, Joint Statistical Meetings, August, 1993, San Francisco, CA.

How to evaluate HIV/AIDS drugs. Japanese Health Foundation, March, 1994, Tokyo, Japan.

In search of the optimal endpoint for AIDS clinical trials. Journée d'Animation Scientifique. ANRS, April, 1994, Paris, France.

Considerations in specifying the duration of followup of antiretroviral trials. 2nd National Conference on Human Retroviruses and Related Infections, February, 1995, Washington,

Can it work? Does it work? Differing expectations for clinical trials. Arguments for pragmatic clinical trials for persons with HIV. American Association for the Advancement of Science, February, 1995, Atlanta, Georgia.

Relationship of serum cholesterol and blood pressure with risk of death from AIDS. American Epidemiological Society, March, 1995, Tampa, Florida.

How much on-site auditing of clinical trials should be performed? Chairperson, 16th Annual Meeting of the Society of Clinical Trials, May, 1995, Seattle, Washington.

How does one measure change in chronic disease? Encounters in Glaucoma Research, June, 1995, Vancouver, British Columbia.

How should clinical endpoints be defined in antiretroviral trials? FDA, AIDS Task Force Workshop: Current Issues in AIDS Clinical Trials: Clinical Endpoint Confirmation Studies, September, 1995, Bethesda, Maryland.

Considerations in specifying the duration of follow-up of antiretroviral trials. Overview and status of HIV: Conference on the Disease Prevention and Control, October, 1995, Pavia, Italy.

Design issues for clinical endpoint trials: Cambridge Healthtech Institute's Second Annual Conference on Surrogate Markers of HIV, October, 1995, Tysons Corners, Virginia.

Role of data and safety monitoring boards. American Academy of Neurology, April 1998, Minneapolis, Minnesota.

Design and analysis issues for equivalence trials. 19th Annual Meeting, Society for Clinical Trials, May, 1998, Atlanta, Georgia.

Making it work: Experience with a centralized biostatistics unit in an academic setting, Joint Statistical Meetings, August, 2000, Indianapolis, Indiana

Challenges to clinical trial design in the setting of HAART (Invited State-of-the-Art Mini-lecture). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, October, 2000, Toronto, Ontario.

Combined endpoints for HIV trials, NIH Endpoint Workshop, February, 2001, Bethesda, Maryland.

Role of the sponsor in data management, steering committee, DSMB, stopping trials and publication, Fourth Cardiovascular Clinical Trials Workshop, December, 2001, Monte Carlo, Monaco.

Practical issues in establishing and operating a data monitoring committee, Drug Information Association Workshop, January, 2002, Bethesda, Maryland.

Predictors of cardiovascular disease: Implications for future HIV clinical trial design, 4th International Workshop on Adverse Drug Reactions and Lipodystrophy, September, 2002, San Diego, California.

Issues in Data Monitoring Committees - Role of Independent Statistician, Duke Clinical Research Institute Symposia, January 2003, Washington D.C.

Prevention of CVD events: 30 years of MRFIT, Festschrift Honoring Dr. Lewis H. Kuller, March 2003, Pittsburgh, PA.

The collection and monitoring of drug safety data, Tools for Pre-Approval of Drug Safety Evaluation, FDA course, May 2003, Washington D.C.

A new generation of clinical endpoint trials in HIV, 3rd Joint Meeting of the Society for Clinical Trials and the International Society for Clinical Biostatistics, July 2003, London

Case Study: CPCRA TOXO Study: Stopped twice, maybe three times. Clinical trial data monitoring committees. Policies, practices and controversies. Drug Information Association, September 2003, Washington D.C.

Rationale, design, and implementation issues for large, long-term international trials in HIV. 6th Congresso Argentino de Sida, November 2003, Buenos Aires, Argentina.

International Research in HIV/AIDS: Challenges and opportunities in the new millennium, Center for Public Health Education, February 2004, Minneapolis, Minnesota.

Composite endpoints. Key issues in endpoint selection and measurement for devices in heart failure. Heart Failure Society of America, April 2004, Washington D.C.

Socioeconomic status, ethnicity, risk factors & cardiovascular disease, Festschrift Honoring the Life and Achievements of Jeremiah Stamler, MD, October 2004, Chicago, Illinois.

Trials in AIDS: lessons for future MS trials? National Multiple Sclerosis Society, December 2004, Washington D.C.

Biostatistical issues in the design of type 1 diabetes trials (Co-chair of workshop), NIDDK, March 2005, Washington D.C.

Importance of follow-up in clinical trials, 2nd Annual PHIDISA Conference, August 2005, Capetown, South Africa.

Alternatives to randomized controlled trials for VAD development, HFSA/FDA Workshop, March 2006, Rockville, Maryland

Data Monitoring Board perspective on the Shingles Prevention Study, Society for Clinical Trials, May 2006, Orlando, Florida

Challenges in the design, implementation, and monitoring of HIV treatment trials, Statistical Society of Canada, May 2006, London, Ontario.

Results of the SMART study, HAART Oversight Committee, June 2006, Paris, France,

The dark side of composite endpoints, European Heart Failure Society, June 2006, Helsinki, Finland.

Randomized Clinical Trials: Designs for the future and obstacles to overcome. Current Issues in Clinical Research, Mayo Clinical Trials Services and the Academic Health Center, University of Minnesota, October 2006, Minneapolis, MN.

When to start HAART. Why an RCT can, and should, be performed. 11th International Workshop on HIV Observational Databases, March 2007, Monte Carlo.

Statistical considerations in interpreting non-randomized trials. Heart Failure Society of America Workshop on Regulatory Issues Surrounding Heart Failure Devices, May 2007, Bethesda, MD.

Changing patterns of morbidity and mortality in HIV disease. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, July 2007, Sydney, Australia.

Considerations in clinical trial design with LVADs. 11th Annual Scientific Meeting, Heart Failure Society of America, September 2007, Washington D.C.

Challenges in the design, organization and conduct of multi-center trials. Current Issues in Clinical Research, Mayo Clinical Trials Services and the Academic Health Center, University of Minnesota, September 2007, Minneapolis, MN.

Practical challenges to keeping the simple in large, simple trials. International Biometric Society, Eastern North American Region, March 2008, Arlington, Virginia.

Interpreting data in the medical literature, Minnesota Academy of Family Physicians, April 2008, St. Paul, Minnesota.

Developing a career in clinical trials: a biostatistician's perspective. 29th Annual Meeting of the Society for Clinical Trials, May 2008, St. Louis, Missouri.

Formation of the INSIGHT Clinical Trials Network – a Case History. Midwest Consortium for Training Clinical Researchers, June 2008, Rochester, Minnesota.

Establishing an infrastructure for a clinical trial network in South Africa. NIAID Workshop on Strengthening Biostatistical Resources in South Africa, September 2009, Bethesda, Maryland.

Commentary on long-term follow-up in clinical trials – ALLHAT experience. American Heart Association Scientific Sessions, November 2009, Orlando, Florida.

Lessons from the field, Collaborative Leadership Development Series, Legal and Regulatory Issues in International Research Collaborations, April 2010, Minneapolis.

Perspectives from SCT Fellows. Society for Clinical Trials, May 2010, Baltimore, MD.

Handling of missing data in clinical trials: findings of a National Research Council Study. Choice of estimand, trial design, and trial conduct. Joint Statistical Meetings, August 2010, Vancouver, British Columbia.

Strategies for preventing cardiovascular disease among individuals infected with HIV. Grand Rounds, University of Rochester School of Medicine and Dentistry, October 2010, Rochester, New York.

Current issues and controversies for clinical trial data monitoring committees. International Biometric Society, Eastern North American Region, March 2011, Miami, Florida.

Emerging statistical issues in the conduct and monitoring of clinical trials, discussant. University of Pennsylvania Annual Conference on Statistical Issues in Clinical Trials, April 2011, Philadelphia, PA.

Missing data in clinical trials. 32nd Annual Meeting of Society for Clinical Trials, May 2011, Vancouver, British Columbia.

A proposal: The establishment of regional data coordinating centers in sub-Saharan Africa for the conduct of large trials. NIAID, NIH Workshop for Biostatistics Capacity Building in Sub-Saharan Africa, June 2011, Gaborone, Botswana.

Compensation for research-related injuries: transforming obligations into action? The START trial: a case example of regulatory impediments to the conduct of publically funded trials. American Society for Bioethics and Humanities, October 2011, Minneapolis, MN.

Prevention of missing data: trial conduct strategies. Short course on the prevention and treatment of missing data in clinical trials, November 2011, Newark, New Jersey.

Rationale and design of two early treatment trials for HIV: START and START-Survival, NIAID, NIH, December 2011, Bethesda.

Incorporating new data and changing standards of care into clinical trials. 19th Conference on Retroviruses and Opportunistic Infections, March 2012, Seattle.

Streamlining regulatory issues: challenges from recent international trials. 2012 Sensible Guidelines Symposium, May 2012, Toronto.

Estimates of CVD mortality risk associated with drug-induced BP elevations. Duke-FDA Cardiac Safety Research Consortium Think Tank, July 2012, Bethesda, Maryland.

The search for missing data: The impact of the National Academies of Science report (Discussant). Joint Statistical Meetings, July 2012, San Diego, California.

Prevention of CVD: Time for a polypill for HIV+ persons. The Global Summit on Combination Polypharmacy for Cardiovascular Disease, September 2012, Hamilton, Ontario.

Prevention of cardiovascular disease in HIV+ individuals: time for a polypill? 1st International Symposium. Present and future of applied sciences in HIV infection, October 2012, Buenos Aires.

Missing data in outcome trials: implications and prevention. Duke FDA Cardiac Safety Research Consortium Annual Meeting, December 2012, Bethesda, Maryland.

Data and safety monitoring boards: current issues and challenges. How blind should the investigators and sponsors be? Joint Statistical Meetings, August 2013, Montreal, Canada.

Considerations in defining and summarizing composite outcomes in clinical trials. ASA Biopharmaceutical Section. FDA-Industry Statistics Workshop, September 2013, Washington, D.C.

Strategies to prevent missing data. Johns Hopkins Symposium and on Handling and Preventing Missing Data, October 2013, Baltimore, MD.

Plus numerous co-authored abstracts and departmental seminars at other institutions.